Virpax Pharmaceuticals, Inc. (VRPX)
NASDAQ: VRPX · Real-Time Price · USD
0.330
+0.018 (5.84%)
At close: Dec 20, 2024, 4:00 PM
0.354
+0.024 (7.21%)
After-hours: Dec 20, 2024, 5:55 PM EST
Virpax Pharmaceuticals Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for VRPX.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for VRPX is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Oct 9, 2024 |
Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $3 | Hold → Strong Buy | Upgrades | $3 | +809.09% | Jul 19, 2024 |
Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 22, 2024 |
Maxim Group | Maxim Group | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +12,021.21% | Jun 9, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.37
from -12.97
EPS Next Year
-0.92
from -3.37
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | n/a | n/a | n/a | |||
Avg | n/a | n/a | n/a | |||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -3.47 | -0.95 | -0.66 |
Avg | -3.37 | -0.92 | -0.64 |
Low | -3.23 | -0.88 | -0.62 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.